Table 3.
Most common adverse reactions with sorafenib plus capecitabine
| Adverse event | CTCAE toxicity grade | |
|---|---|---|
| All grades, n (%) | Grade ≥3, n (%) | |
| Palmar‐plantar erythrodysesthesia syndrome | 36 (85.7) | 16 (38.1) |
| Fatigue | 26 (61.9) | 5 (11.9) |
| Nausea | 17 (40.5) | 1 (2.4) |
| Anorexia | 17 (40.5) | 0 |
| Diarrhea | 16 (38.1) | 1 (2.4) |
| Vomiting | 11 (26.2) | 1 (2.4) |
| Hypertension | 9 (21.4) | 6 (14.3) |
| Abdominal pain | 9 (21.4) | 4 (9.5) |
| Oral mucositis | 9 (21.4) | 2 (4.8) |
| Weight loss | 9 (21.4) | 0 |
Abbreviation: CTCAE, Common Terminology Criteria for Adverse Events version 4.0.